Evaluation of the pain intensity of pain and quality of life of patients with osteoporosis diagnosis and teriparatide treatment

Abstract

A descriptive, retrospective study to determine whether treatment with recombinant parathyroid hormone (teriparatide)reduces pain in patients with osteoporosis, in the endocrinology unitat the Military Hospital in Colombia in 008. Objectives: 1) to describe demographic  aspects of osteoporosis patients managed with teriparatide.2) to determine frequency of patients requiring analgésic adjuvant therapy for the management of pain associated withosteoporosis. 3) to determine whether the use of teriparatide reduced pain in patients with osteoporosis. Materials and Methods: From twenty patients with osteoporosis who received teriparatide,12 were included in the study in a period from January to December 2008. To evaluate the quality of life and pain intensity,the SF36 questionnaire and visual analog pain scale was used, respectively. All data from the survey sand the SF36 form, were stored in data bases using the program Excel 2011. A descriptive statistical analysis was performed  using the frequency representation as a percentage. To determine differences in the frequency of occurrence of an event,Chi² test was used. P < 0.05 was considered as significant. Results: Teriparatide treatment significantly decreased frequency of patients requiring analgésica djuvant therapy with NSAIDs and opiates at 6 months follow-up (P=0.04,Chi2). Conclusions: results suggest a beneficial effect of pain relief and quality of life with treatment for osteoporosis with teriparatide. Conclusions: results suggest a beneficial effect of pain relief and quality of life with treatment for osteoporosis with teriparatide.